MapLight Therapeutics Inc. Q3 net loss rises to USD 29.4 million, up 55 percent
Reuters
Dec 04, 2025
MapLight <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Q3 net loss rises to USD 29.4 million, up 55 percent
MapLight Therapeutics Inc. reported its third quarter (Q3) 2025 financial results. Research and development expenses for Q3 2025 totaled USD 27.1 million, an increase of 61 percent, primarily driven by higher clinical trial, employee-related, and formulation and CMC expenses. General and administrative expenses for the period were USD 4.4 million. Total operating expenses reached USD 31.5 million for Q3 2025. Net loss for the quarter was USD 29.4 million. For the nine-month period ended September 30, 2025, research and development expenses were USD 73.7 million and general and administrative expenses were USD 12.0 million. Total operating expenses for the nine-month period amounted to USD 85.7 million. The company also reported that it raised USD 296.5 million in gross proceeds from its initial public offering and concurrent private placement in October 2025, and that cash, cash equivalents, and short-term investments are sufficient to fund operations through 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596649-en) on December 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.